Difference between revisions of "MSK Biomarker Ctte"
Jump to navigation
Jump to search
| (4 intermediate revisions by the same user not shown) | |||
| Line 9: | Line 9: | ||
'''Approved call summaries:''' | '''Approved call summaries:''' | ||
| − | *[[Media:2022- | + | *[[Media:2022-09-27_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|September 27, 2022]] |
| − | *[[Media:2022- | + | *[[Media:2022-07-26_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|July 26, 2022]] |
| − | *[[Media:2022- | + | *[[Media:2022-06-28_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|June 28, 2022]] |
'''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | '''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | ||
Revision as of 17:17, 22 November 2022
Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD
RSNA Staff Support: Susan Stanfa
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
Meetings
Approved call summaries:
MSK Biomarker Committee Call Summaries Archive
Profile Documents
- MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease 2021-09-25 - Consensus Profile
- MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease 2020-01-28 - Public Comment Profile